Baxter BioPharma Solutions

White Papers / Tech Papers

Assurance of the vacuum integrity of freeze - dryers used for the manufacture of sterile pharmaceutical products is essential for GMP operations; however, there is currently no generally accepted scientific rationale for establishing acceptance crite…

Formulation, process, and analytical development for antibody - drug conjugates, or ADCs, is complex. While the development of an aqueous solution formulation may be preferred over a lyophilized product, it is useful to initially pursue a dual path a…

A common approach to process development for lyophilized products is to thermally characterize the solution formulation to determine the critical product temperature that should not be exceeded during primary drying. This is conducted using different…

Formulation and process development for injectable products are typically conducted at laboratory-scale. Laboratory-scale equipment is useful and necessary during development when there is little technical information available and especially when th…

The ultimate goal of formulation development is a stable product. In the case of a protein product, that can be defined as delivering the correct dose, in the native secondary and tertiary structure, without unintended chemical modifications, and fre…

Company Headquarters

Company Description

Baxter’s BioPharma
Solutions business
collaborates with
pharmaceutical
companies to support
commercialization
objectives for their
molecules. As a
parenterals
specialist with over
85 years of
expertise, BioPharma
Solutions offers
contract
manufacturing
form/fill/finish
services and
solutions for
injectables designed
to meet complex and
traditional sterile
manufacturing
challenges. As a
global injectables
specialist, we can
help solve unique
challenges with
confidence of
delivery, service
and integrity.
Baxter has
manufacturing sites
across the globe in
support of a diverse
portfolio of
delivery systems and
manufacturing
solutions. The
strength of
Baxter’s global
network lies in
efficient, quality
cGMP manufacturing
– enabling
BioPharma Solutions
to deliver
cost-effective
results built on
best practices and
operational
excellence.

Company Description

BioPharma Solutions, a business unit of Baxter, collaborates with pharmaceutical companies to support their commercialization objectives by providing scientific expertise, sterile contract manufacturing solutions, parenteral delivery systems, and customized support services needed to meet the unique challenges that parenteral products face.

With more than 50 manufacturing facilities across six continents, Baxter’s global presence provides opportunities for unique manufacturing collaborations to provide the most value for our partners. The power of an extensive global network lies in the coordination of, and efficiencies resulting from, a systemic approach to cGMP manufacturing.

Baxter’s BioPharma Solutions facility in Bloomington, Indiana, was recognized for the fifth time as Best Contract Manufacturing Organization at the annual Vaccine Industry Excellence (ViE) Awards, held during the 2017 World Vaccine Congress in…

Experience Makes the Difference
Optimizing lyophilization cycle times and improving stability for complex injectables is a critical component of parenteral product development. With this understanding, BioPharma Solutions established the Lyophiliz…

Baxter has been honored to be recognized globally with various awards and distinctions by the industry, as well as by sustainability, community support and environmental organizations. Download the attached for a sampling, with a full list available…

Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies. You can obtain detailed information about the use of cookies on our website by clicking on "More information”.